| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | - | - | -62.5% |
| Operating Income | ¥-9.6B | ¥-8.2B | -17.3% |
| Ordinary Income | ¥-9.5B | ¥-8.1B | -17.2% |
| Net Income | ¥-9.6B | ¥-8.2B | -17.2% |
| ROE | -86.0% | -88.2% | - |
FY2026 Q3 results show a loss-making structure with Operating Loss of 9.6B yen (YoY -17.3% deterioration), Ordinary Loss of 9.5B yen (-17.2%), and Net Loss of 9.6B yen (-17.2%). Revenue declined sharply by 62.5% YoY to near-zero levels. SG&A expenses of 9.6B yen remained the primary cost driver, exceeding revenue and generating operational losses. Despite negative earnings, the company maintains a strong liquidity position with cash and deposits of 9.4B yen and current ratio of 709.0%. The equity ratio stands at 81.4%, though retained earnings deficit expanded to -47.6B yen from -38.1B yen YoY, representing a 25% deterioration in accumulated losses. Full-year FY2026 forecast anticipates Operating Loss of 11.8B yen and Net Loss of 11.7B yen (EPS -12.88 yen) with no dividend. Basic EPS was -9.07 yen, showing 11.9% improvement from prior period's -10.30 yen due to lower per-share loss allocation.
Revenue declined 62.5% YoY to effectively zero, indicating a significant disruption to core revenue streams, likely related to product pipeline delays, licensing timing gaps, or strategic shifts in the pharmaceutical development cycle. With no segment breakdown available, the revenue contraction appears broad-based rather than isolated to specific divisions. On the profit side, SG&A expenses of 9.6B yen dominated the cost structure in the absence of cost of sales, reflecting fixed operational overhead including research and development, administrative functions, and corporate infrastructure. The operating loss of 9.6B yen expanded 17.3% YoY from 8.2B yen, driven by the combination of revenue decline and persistent high fixed costs. Non-operating income contributed a modest 0.1B yen offset by non-operating expenses of 0.1B yen, primarily FX losses, resulting in an Ordinary Loss of 9.5B yen nearly equivalent to the operating loss. The income tax expense was negligible at 0.0B yen given the loss position, leading to Net Loss of 9.6B yen. The minimal gap between operating and ordinary income of approximately 0.1B yen indicates limited non-operating leverage. This represents a revenue down / profit down pattern, with revenue collapse driving loss expansion against a relatively rigid cost base.
[Profitability] ROE of -86.0% reflects severe negative earnings against equity base, deteriorating from operating structure. Operating margin is deeply negative given operating loss of 9.6B yen against minimal revenue, with net profit margin similarly impaired at negative territory. The financial leverage ratio stands at 1.23x (total assets 13.7B yen / equity 11.1B yen), indicating conservative debt usage despite loss-making operations. [Cash Quality] Cash and deposits of 9.4B yen provide substantial liquidity buffer, representing 68.8% of total assets. Cash coverage of current liabilities stands at 5.1x (cash 9.4B yen / current liabilities 1.9B yen), ensuring near-term payment capacity despite ongoing losses. [Investment Efficiency] Asset turnover cannot be meaningfully calculated given near-zero revenue against total assets of 13.7B yen, highlighting inactive revenue generation relative to asset base. ROIC of -573.9% signals extreme capital inefficiency with negative returns on invested capital. [Financial Health] Equity ratio of 81.4% demonstrates strong capitalization with equity of 11.1B yen supporting assets of 13.7B yen. Current ratio of 709.0% (current assets 13.1B yen / current liabilities 1.9B yen) indicates exceptional short-term liquidity. Debt-to-equity ratio of 0.23x reflects minimal leverage. However, retained earnings deficit of -47.6B yen represents accumulated losses exceeding 4.3x current equity, posing medium-term sustainability concerns if losses persist.
Cash and deposits increased to 9.4B yen, comprising 68.8% of total assets and providing substantial liquidity cushion despite operating losses. The balance sheet shows working capital of 11.3B yen (current assets 13.1B yen less current liabilities 1.9B yen), suggesting effective short-term asset management even in loss-making conditions. Non-current liabilities of 0.7B yen and current portion of bonds of 0.2B yen indicate manageable debt service obligations. Cash coverage of short-term liabilities stands at 5.1x, well above safety thresholds and ensuring payment capacity for at least several quarters of operations at current burn rates. The equity base of 11.1B yen grew from 9.2B yen YoY, implying potential equity financing or capital injection of approximately 1.9B yen offsetting the 9.6B yen net loss, which would have otherwise reduced equity to near-zero levels. This inferred financing activity indicates management's proactive capital management to sustain operations through the development phase.
Operating loss of 9.6B yen versus ordinary loss of 9.5B yen shows net non-operating contribution of approximately 0.1B yen negative, reflecting minimal impact from financial activities. Non-operating income of 0.1B yen was largely offset by non-operating expenses of 0.1B yen, primarily FX losses, indicating limited financial income or investment gains. With revenue effectively zero, non-operating items represent an immaterial portion of the income statement. The absence of extraordinary items such as impairment losses (0.0B yen reported) suggests no major asset write-downs or restructuring charges in the quarter. However, without disclosed operating cash flow data, the alignment between accrual-based losses and actual cash outflows cannot be directly verified. The persistent loss structure and negative profit before tax of 9.5B yen with negligible tax expense indicates limited accrual-based earnings manipulation risk but raises questions about the sustainability of operations absent external funding.
Full-year FY2026 guidance projects Revenue of 0.0B yen, Operating Loss of 11.8B yen, Ordinary Loss of 11.6B yen, and Net Loss of 11.7B yen with EPS forecast of -12.88 yen. Q3 cumulative net loss of 9.6B yen represents 82.1% progress against the full-year loss forecast of 11.7B yen, indicating loss realization is running faster than typical linear quarterly phasing. This suggests Q4 may see lower losses of approximately 2.1B yen if the guidance holds, potentially reflecting anticipated cost reductions or partial revenue recognition in the final quarter. The revenue forecast of zero for the full year aligns with Q3 actuals and indicates no material product sales or licensing income is expected in the remainder of FY2026. The widening loss trajectory from Q3 run-rate to full-year implies operational burn is expected to continue, though at a decelerating pace. Dividend forecast remains at zero yen with no revision signaled this quarter.
Revenue recovery timing remains the foremost risk, with revenue declining 62.5% YoY to near-zero levels and full-year guidance of zero revenue. Without successful product commercialization, licensing agreements, or milestone payments, the company lacks organic cash generation to offset ongoing SG&A of approximately 9.6B yen quarterly. Second, retained earnings deficit expanded to -47.6B yen, representing 25% YoY deterioration and accumulated losses now 4.3x current equity of 11.1B yen. Continued quarterly losses of 9-12B yen would deplete equity within 3-4 quarters absent additional capital raises, creating medium-term solvency pressure despite current strong liquidity. Third, capital efficiency metrics show ROIC of -573.9%, reflecting severe misalignment between invested capital and returns. This suggests high ongoing R&D or operational investments without corresponding revenue generation, and without pipeline progress or strategic partnerships, return on capital may remain deeply negative for extended periods.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial metrics show significant divergence from pharmaceutical industry medians as of 2025-Q3. Profitability metrics including ROE of -86.0% compare unfavorably to industry median of -35.8%, placing the company in the lower quartile of sector performance (IQR: -91.4% to -6.1%). Operating margin is deeply negative, whereas industry median of -218.2% suggests the sector broadly faces profitability challenges, though the company's position remains below median. Financial health indicators are mixed: Equity Ratio of 81.4% significantly exceeds industry median of 67.8% (IQR: 62.1%-79.1%), indicating stronger capitalization than peers. Current Ratio of 709.0% vastly outperforms industry median of 6.62x (IQR: 4.66x-9.18x), reflecting exceptional liquidity positioning. However, efficiency metrics lag: ROIC of -573.9% is substantially below industry median of -0.32 (IQR: -1.45 to -0.02), signaling extreme capital inefficiency relative to sector norms. Revenue Growth YoY of -62.5% underperforms industry median of -12.5% (IQR: -22.1% to -2.5%), indicating more severe top-line contraction than typical for development-stage pharmaceutical firms.
(Industry: Pharmaceutical sector development-stage companies, Comparison: Prior fiscal periods 2025-Q3, Source: Proprietary analysis)
Near-term liquidity strength provides operational runway despite loss structure, with cash of 9.4B yen covering approximately 3-4 quarters of current burn rate around 9.6B yen per quarter, offering a window for pipeline progression or strategic transactions before capital constraints bind. The equity raise inferred from balance sheet movements (equity increased 1.9B yen YoY despite 9.6B yen net loss) signals active capital management and investor willingness to fund the development cycle, though dilution impact on existing shareholders warrants monitoring. Structural inflection depends critically on revenue catalyst materialization, whether through drug approval, licensing deals, or milestone receipts, as the current zero-revenue profile is unsustainable beyond the cash runway and continued external funding would further dilute equity holders absent tangible commercial progress in pipeline assets.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.